Join the DDA or

Teva ranitidine recall

Precautionary action while contaminant investigation in ongoing

October 18th 2019

Tagged: MHRA alert

By MHRA

Teva UK Limited trading as ratiopharm GmbH is recalling the following batches of ranitidine effervescent tablets 150mg and 300mg:

Batch Number Expiry Date Pack Size First Distributed
17007672 30/04/2020 1 x 60 01/09/2017
17011546 30/06/2020 1 x 60 19/12/2017
17017838 30/09/2020 1 x 60 28/03/2018
18001231 31/12/2020 1 x 60 15/08/2018
18006590 31/03/2021 1 x 60 20/11/2018
18006591 31/03/2021 1 x 60 03/12/2018
18010644 30/06/2021 1 x 60 06/11/2018
18010645 30/06/2021 1 x 60 05/06/2019

Ranitidine Effervescent Tablets 300mg (PL 15773/067)

Batch Number Expiry Date Pack Size First Distributed
17001878 31/01/2020 1 x 30 27/06/2017
17011702 30/06/2020 1 x 30 09/07/2018

Generic Name: Ranitidine

This is a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.

Healthcare professionals are asked to quarantine all remaining stock without delay and return it to your supplier using your supplier’s approved process.

Patients are advised to not stop taking their medication as the health risk of discontinuing the medicine is higher than the potential risk presented by the contaminant. A treatment review is not necessary until the next routine appointment.

For stock control enquiries please contact Teva Customer Solutions team on 0800 590502 or customer.services@tevauk.com.

For medical information enquiries please contact Teva UK Medical Information Department on 0207 540 7337 or UK.Safety@tevauk.com.

For all the latest news of the 2020 DDA annual conference...

Learn more